Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Phathom Pharmaceuticals
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
August 19, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 30, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
July 29, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
July 18, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 28, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 15, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
April 29, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
March 26, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
February 29, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
February 13, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 14, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
HTGC
PHAT
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 06, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 28, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
November 01, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 30, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
October 25, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 26, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 21, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
August 10, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 12, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
June 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
June 01, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 23, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Tickers
PHAT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.